Clinical and therapeutic implications of BRAF fusions in histiocytic disorders

Blood Cancer J. 2022 Jun 28;12(6):97. doi: 10.1038/s41408-022-00693-7.
No abstract available

Publication types

  • Letter

MeSH terms

  • Humans
  • Mutation
  • Protein Kinase Inhibitors* / therapeutic use
  • Proto-Oncogene Proteins B-raf* / genetics

Substances

  • Protein Kinase Inhibitors
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf